No causal relationship has been established in humans to date, and population-level data from large GLP-1 user cohorts have not shown a clear increase in MTC incidence.[5] That said, there are defined contraindications: GLP-1 therapy is not appropriate for patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2 syndrome)
However, emerging research suggests potential benefits for women with polycystic ovary syndrome (PCOS), a condition characterised by insulin resistance and multiple ovarian follicles
The SELECT cardiovascular outcomes trial, whose results were fully incorporated into regulatory labeling by 2024, directly catalyzed a new wave of prescribing for semaglutide in cardiology settings, materially broadening the addressable API volume requirement
Opt for Bland, Simple Carbohydrates When nausea strikes, many people find relief by returning to basics
This allowed for assessment of the impact of long-term use, and contextualized use as compared to clinical trials
